《2013 ESMO臨床實(shí)踐指南：成人急性髓性白血病的診斷、治療與隨訪(fǎng)》  內容預覽
    Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    制定者：歐洲腫瘤內科學(xué)會(huì )（ESMO,European Society for Medical Oncology）

    出處：  Ann Oncol. 2013 Aug 22.

    該指南為歐洲腫瘤內科學(xué)會(huì )2013年版的成人急性髓性白血病診斷、治療與隨訪(fǎng)指南，指南介紹了成人急性髓性白血病的病因與流行病學(xué)、診斷與分子生物學(xué)、風(fēng)險評估與診斷因素、治療、個(gè)體化醫療以及療效評估與預后。

    指南推薦要點(diǎn)：

    Diagnostic work-up of AML must in include morphology of pe**heral blood and bone marrow, cytogenetics and molecular genetics assessed before start of therapy

    HLA-typing of patient and family members to plan for allogeneic stem cell transplantation where indicated

    AML should only be treated in specialised and experienced centres offering a multidisciplinary approach, and the possibility of clinical trials

    AML therapy with curative intent includes induction chemotherapy （incorporating an anthracycline and cytarabine）， consolidation which in intermediate to high-risk patients may incorporate allogeneic stem cell transplantation

    APL needs a specific therapy approach. ATRA must be started whenever in a case of leukaemia the differential diagnosis of APL is considered, and combined with anthracycline-based chemotherapy once the diagnosis of APL is confirmed

ESMO急性髓性白血病診治隨訪(fǎng)指南:
http://ziyuan.iiyi.com/source/down/2321399.html